SEC Filings
Shattuck Labs' Quarterly Loss Reaches $25.2 Million As Crohn's Trial Costs Climb
The biotech's research spending rose to $21.6 million from $7.6 million, and it says its cash should last into 2029.
Shattuck Labs (STTK) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The biotech's research spending rose to $21.6 million from $7.6 million, and it says its cash should last into 2029.
SEC Filings
BlackRock reported 5,339,458 shares of the Crohn's-focused biotech, with sole voting power over 5,221,737 of them.